Last reviewed · How we verify
Tindal (ACETOPHENAZINE)
Tindal (acetophenazine) is a small molecule drug originally developed by Schering and currently owned by the same company. It targets the D(2) dopamine receptor and is used to treat psychotic disorders. Tindal was FDA-approved in 1961 and is now off-patent, meaning there are no active Orange Book patents. As a result, there are currently no generic manufacturers of the drug. Despite its off-patent status, key safety considerations for Tindal are not well-documented due to a lack of available information on its pharmacokinetics.
At a glance
| Generic name | ACETOPHENAZINE |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | acetophenazine |
| Target | D(2) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1961 |
Approved indications
- Psychotic disorder
Common side effects
Drug interactions
- cisapride
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |